NCT02245932

Resveratrol In Chronic Obstructive Pulmonary Disease (COPD) Patients (CARMENS-trial)

The Effect of Resveratrol on Metabolism and Cardiovascular Risk Profile in Patients With Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Maastricht University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to investigate the efficacy of resveratrol on mitochondrial function in patients with COPD. The secondary objective is to investigate the effect of resveratrol on body composition, inflammatory status and mechanistic markers in blood, adipose and muscle tissue as well as a comprehensive assessment of metabolicand physical performance profile known to be affected by resveratrol.

Detailed description

Rationale: Patients with COPD are often chaacterized by disturbed metabolic health affecting physical and cognitive function, which is reflected in altered body composition. current studies in healthy subjects suggest that resveratrol improves metabolic health by enhancing muscle mitochondrial function and adipose tissue morphology. Study design: Proof-of-concept randomized placebo-controlled double blinded clinical trial of 4 weeks. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects may be confronted with certain inconveniences and risks. Subjects will be asked to wear an accelerometer two times for one week. During the entire study period subjects will visit the MUMC+ 2 times for various non-invasive measurements (questionnaires, anthropometry, and physical function test) as well as some minor invasive procedures (venous blood sampling and muscle and fat biopsies) which can cause a local haematoma afterwards. However, the patients will be informed about their metabolic and cardiovascular health, which we expect to be positively affected by the intervention. In addition, all patients will receive a lifestyle advice tailored to their health status.

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Resveratrol	4 weeks of 150 mg resveratrol (2 times 75mg/day)
DIETARY_SUPPLEMENT	Placebo	4 weeks of placebo supplementation (two doses per day)

Timeline

• Start date: 2015-01-01
• Primary completion: 2017-11-01
• Completion: 2017-11-01
• First posted: 2014-09-22
• Last updated: 2019-05-17

Locations

1 site across 1 country: Netherlands